Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
暂无分享,去创建一个
Boris Gorovits | P. Frost | S. Stephens | N. Damle | B. Gorovits | E. Boghaert | J. Dijoseph | Latha Sridharan | Arthur Kunz | Maureen M. Dougher | Philip Frost | John F DiJoseph | Douglas C Armellino | Erwin R Boghaert | Kiran Khandke | Maureen M Dougher | Philip R Hamann | Chandrasekhar Udata | Justin K Moran | Andrew G Popplewell | Sue Stephens | Nitin K Damle | L. Sridharan | K. Khandke | D. Armellino | A. Kunz | P. Hamann | M. Dougher | J. Moran | C. Udata | A. Popplewell | P. R. Hamann
[1] M. Walker,et al. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.
[2] P. Frost,et al. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.
[3] M. Gibaldi,et al. Pharmacokinetics, Second Edition , 1982 .
[4] Kreitman Rj. Toxin-labeled monoclonal antibodies. , 2001 .
[5] R. Kreitman. Recombinant toxins for the treatment of cancer. , 2003, Current opinion in molecular therapeutics.
[6] I. Bernstein,et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) , 2002, Leukemia.
[7] J. Leonard,et al. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). , 2002, Seminars in oncology.
[8] A. Varki,et al. Siglecs, sialic acids and innate immunity. , 2001, Trends in immunology.
[9] M. J. Mattes,et al. Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. , 1996, Cancer research.
[10] P. Crocker,et al. New Functions for the Sialic Acid‐Binding Adhesion Molecule CD22, a Member of the Growing Family of Siglecs , 2001, Scandinavian journal of immunology.
[11] W. Wilson,et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.
[12] R. Kreitman,et al. Toxin-labeled monoclonal antibodies. , 2001, Current pharmaceutical biotechnology.
[13] R. Wallace,et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. , 1993, Cancer research.
[14] Irwin Hollander,et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.
[15] D. Newton,et al. Specifically Targeting the CD22 Receptor of Human B-cell Lymphomas with RNA Damaging Agents: A New Generation of Therapeutics , 2002, Leukemia & lymphoma.
[16] I. Bernstein,et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.
[17] G. Ellestad,et al. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. , 1988, Science.
[18] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] I. Bernstein,et al. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties , 1989, The Journal of experimental medicine.
[20] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. Sausville,et al. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] M. Berger,et al. Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse , 2002, Investigational New Drugs.
[23] O. Press,et al. Constitutive endocytosis and degradation of CD22 by human B cells. , 1995, Journal of immunology.
[24] M. Berger,et al. Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse , 2001, Journal of clinical pharmacology.
[25] P. Trail,et al. Monoclonal antibody drug conjugates in the treatment of cancer. , 1999, Current opinion in immunology.
[26] J. Leonard,et al. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). , 2002, Seminars in oncology.
[27] Ira Pastan,et al. Immunotoxins in cancer therapy. , 1999, Current opinion in investigational drugs.
[28] R. Gressin,et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. , 2003, Blood.
[29] M. Siegel,et al. Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins .beta.1Br, .gamma.1Br, .alpha.2I, .alpha.3I, .beta.1I, .gamma.1I, and .delta.1I , 1992 .
[30] J. Thorson,et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. , 2000, Current pharmaceutical design.
[31] S. Sato,et al. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. , 1997, Annual review of immunology.
[32] L. Santos‐Argumedo,et al. Expression and Function of CD22, a B‐cell Restricted Molecule * , 2002, Scandinavian journal of immunology.
[33] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.